Literature DB >> 18474516

Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

Francesca Lavatelli1, David H Perlman, Brian Spencer, Tatiana Prokaeva, Mark E McComb, Roger Théberge, Lawreen H Connors, Vittorio Bellotti, David C Seldin, Giampaolo Merlini, Martha Skinner, Catherine E Costello.   

Abstract

In systemic amyloidoses, widespread deposition of protein as amyloid causes severe organ dysfunction. It is necessary to discriminate among the different forms of amyloid to design an appropriate therapeutic strategy. We developed a proteomics methodology utilizing two-dimensional polyacrylamide gel electrophoresis followed by matrix-assisted laser desorption/ionization mass spectrometry and peptide mass fingerprinting to directly characterize amyloid deposits in abdominal subcutaneous fat obtained by fine needle aspiration from patients diagnosed as having amyloidoses typed as immunoglobulin light chain or transthyretin. Striking differences in the two-dimensional gel proteomes of adipose tissue were observed between controls and patients and between the two types of patients with distinct, additional spots present in the patient specimens that could be assigned as the amyloidogenic proteins in full-length and truncated forms. In patients heterozygotic for transthyretin mutations, wild-type peptides and peptides containing amyloidogenic transthyretin variants were isolated in roughly equal amounts from the same protein spots, indicative of incorporation of both species into the deposits. Furthermore novel spots unrelated to the amyloidogenic proteins appeared in patient samples; some of these were identified as isoforms of serum amyloid P and apolipoprotein E, proteins that have been described previously to be associated with amyloid deposits. Finally changes in the normal expression pattern of resident adipose proteins, such as down-regulation of alphaB-crystallin, peroxiredoxin 6, and aldo-keto reductase I, were observed in apparent association with the presence of amyloid, although their levels did not strictly correlate with the grade of amyloid deposition. This proteomics approach not only provides a way to detect and unambiguously type the deposits in abdominal subcutaneous fat aspirates from patients with amyloidoses but it may also have the capability to generate new insights into the mechanism of the diseases by identifying novel proteins or protein post-translational modifications associated with amyloid infiltration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474516      PMCID: PMC2494907          DOI: 10.1074/mcp.M700545-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  51 in total

1.  Plasma protein map: an update by microsequencing.

Authors:  G J Hughes; S Frutiger; N Paquet; F Ravier; C Pasquali; J C Sanchez; R James; J D Tissot; B Bjellqvist; D F Hochstrasser
Journal:  Electrophoresis       Date:  1992 Sep-Oct       Impact factor: 3.535

2.  Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: a likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice?

Authors:  Qinghai Zhang; Jeffery W Kelly
Journal:  Biochemistry       Date:  2005-06-28       Impact factor: 3.162

3.  Fragments of the constant region of immunoglobulin light chains are constituents of AL-amyloid proteins.

Authors:  K E Olsen; K Sletten; P Westermark
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

4.  Extended analysis of AL-amyloid protein from abdominal wall subcutaneous fat biopsy: kappa IV immunoglobulin light chain.

Authors:  K E Olsen; K Sletten; P Westermark
Journal:  Biochem Biophys Res Commun       Date:  1998-04-28       Impact factor: 3.575

Review 5.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

6.  Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application.

Authors:  R L Comenzo; D Michelle; M LeBlanc; J Wally; Y Zhang; G Kica; S Karandish; C F Arkin; D G Wright; M Skinner; J McMannis
Journal:  Transfusion       Date:  1998-01       Impact factor: 3.157

7.  Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons.

Authors:  M Karas; F Hillenkamp
Journal:  Anal Chem       Date:  1988-10-15       Impact factor: 6.986

8.  Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis.

Authors:  M A Duston; M Skinner; R F Meenan; A S Cohen
Journal:  Arthritis Rheum       Date:  1989-01

9.  Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes.

Authors:  M Welschof; P Terness; F Kolbinger; M Zewe; S Dübel; H Dörsam; C Hain; M Finger; M Jung; G Moldenhauer
Journal:  J Immunol Methods       Date:  1995-02-27       Impact factor: 2.303

10.  Use of subcutaneous abdominal fat biopsy specimen for detailed typing of amyloid fibril protein-AL by amino acid sequence analysis.

Authors:  P Westermark; L Benson; J Juul; K Sletten
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

View more
  43 in total

Review 1.  Systemic amyloidosis: a challenge for the rheumatologist.

Authors:  Federico Perfetto; Alberto Moggi-Pignone; Riccardo Livi; Alessio Tempestini; Franco Bergesio; Marco Matucci-Cerinic
Journal:  Nat Rev Rheumatol       Date:  2010-06-08       Impact factor: 20.543

2.  Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.

Authors:  Ruiyi Ren; Zhenning Hong; Haiyan Gong; Kate Laporte; Martha Skinner; David C Seldin; Catherine E Costello; Lawreen H Connors; Vickery Trinkaus-Randall
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

3.  Current treatment of AL amyloidosis.

Authors:  Giovanni Palladini; Giampaolo Merlini
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

Review 4.  Cardiac amyloidosis: the heart of the matter.

Authors:  Federico Perfetto; Francesco Cappelli; Franco Bergesio; Gabriele Ciuti; Maria Cristina Porciani; Luigi Padeletti; Alberto Moggi Pignone
Journal:  Intern Emerg Med       Date:  2011-07-08       Impact factor: 3.397

5.  Formation of amyloid fibers by monomeric light chain variable domains.

Authors:  Boris Brumshtein; Shannon R Esswein; Meytal Landau; Christopher M Ryan; Julian P Whitelegge; Martin L Phillips; Duilio Cascio; Michael R Sawaya; David S Eisenberg
Journal:  J Biol Chem       Date:  2014-08-19       Impact factor: 5.157

6.  Stabilization of amyloidogenic immunoglobulin light chains by small molecules.

Authors:  Gareth J Morgan; Nicholas L Yan; David E Mortenson; Enrico Rennella; Joshua M Blundon; Ryan M Gwin; Chung-Yon Lin; Robyn L Stanfield; Steven J Brown; Hugh Rosen; Timothy P Spicer; Virneliz Fernandez-Vega; Giampaolo Merlini; Lewis E Kay; Ian A Wilson; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-10       Impact factor: 11.205

Review 7.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 8.  Systemic amyloidoses.

Authors:  Luis M Blancas-Mejía; Marina Ramirez-Alvarado
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

9.  The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.

Authors:  Gareth J Morgan; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2016-08-26       Impact factor: 5.469

10.  Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.

Authors:  Marta Marin-Argany; Yi Lin; Pinaki Misra; Angela Williams; Jonathan S Wall; Kyle G Howell; Laura R Elsbernd; Megan McClure; Marina Ramirez-Alvarado
Journal:  J Biol Chem       Date:  2016-07-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.